Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

22.57 -1.61 (-6.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,992,973
Open 24.57
Bid (Size) 22.41 (100)
Ask (Size) 23.02 (100)
Prev. Close 24.18
Today's Range 22.41 - 24.57
52wk Range 9.955 - 24.34
Shares Outstanding 144,311,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Adaptive Biotechnologies Q2 Earnings Call Highlights ↗
Adaptive Biotechnologies (NASDAQ:ADPT) reported second-quarter results marked by accelerating growth in its minimal residual disease, or MRD, business, improved margins and an increased full-year... 
Via MarketBeat
Topics Earnings
Adaptive Biotechnologies (NASDAQ:ADPT) Surges After Q2 Beat and Raised Guidance ↗
Via Chartmill

Performance

YTD
+41.9%
+41.9%
1 Month
+5.2%
+5.2%
3 Month
+60.1%
+60.1%
6 Month
+22.9%
+22.9%
1 Year
+116.2%
+116.2%

More News

Read More
News headline image
Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run ↗
Via The Motley Fool
Topics Regulatory Compliance
Adaptive Biotechnologies (NASDAQ:ADPT) Surges 6% on Q1 Beat and Raised MRD Guidance ↗
Via Chartmill
News headline image
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference ↗
Via MarketBeat
News headline image
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive (ADPT) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors. ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a look ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotech Insider Sale of 180,000 Shares Tied to Tax Event as Stock Jumps 70% in a Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Adaptive Biotechnologies Insider Sells $1 Million in Stock After a Doubling in Share Price ↗
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Adaptive Biotechnologies Corporation - Common Stock publicly traded?
Yes, Adaptive Biotechnologies Corporation - Common Stock is publicly traded.
What exchange does Adaptive Biotechnologies Corporation - Common Stock trade on?
Adaptive Biotechnologies Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Adaptive Biotechnologies Corporation - Common Stock?
The ticker symbol for Adaptive Biotechnologies Corporation - Common Stock is ADPT on the Nasdaq Stock Market
What is the current price of Adaptive Biotechnologies Corporation - Common Stock?
The current price of Adaptive Biotechnologies Corporation - Common Stock is 22.57
When was Adaptive Biotechnologies Corporation - Common Stock last traded?
The last trade of Adaptive Biotechnologies Corporation - Common Stock was at 07/31/26 04:00 PM ET
What is the market capitalization of Adaptive Biotechnologies Corporation - Common Stock?
The market capitalization of Adaptive Biotechnologies Corporation - Common Stock is 3.26B
How many shares of Adaptive Biotechnologies Corporation - Common Stock are outstanding?
Adaptive Biotechnologies Corporation - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.